Mucosal Involvement in Bullous Pemphigoid: Severity Indicator and Associated Clinical Features from a Retrospective Cohort Study. [PDF]
Cui S +6 more
europepmc +1 more source
A case series of immune checkpoint inhibitor-induced bullous pemphigoid successfully treated with dupilumab and evidence for the BP180 midportion epitope as a preferential autoantigenic target. [PDF]
Didona D +5 more
europepmc +1 more source
Localized bullous pemphigoid masquerading as venous leg ulcers in a patient with chronic venous insufficiency. [PDF]
Perry A, Namazian S, Vu T, Mervis J.
europepmc +1 more source
Stapokibart's clinical effectiveness in treating moderate-to-severe bullous pemphigoid in the elderly. [PDF]
Du N, Wang Y, Yang J, Lv X, Min W.
europepmc +1 more source
Vedolizumab-induced Bullous Pemphigoid: A Case Report with Serological Evidence and Mechanistic Insights. [PDF]
Feng X, Li J, Li X, Zhang Y, Li W.
europepmc +1 more source
Regulatory T cells in bullous pemphigoid: biological characteristics, dysfunction, and pathogenic roles. [PDF]
Wang Z +7 more
europepmc +1 more source
Autoimmunity to Collagen XVII (BP180-Ag2) in Pemphigoid Associated With Parkinson's Disease. [PDF]
Cid-Puente R +5 more
europepmc +1 more source
Case Report: Dupilumab in difficult-to-treat bullous pemphigoid at the University Hospital Schleswig-Holstein, Campus Kiel. [PDF]
Mehrjerdian Y +5 more
europepmc +1 more source
Diagnostic Agreement in Subepidermal Blistering Diseases: Is ELISA Test Reliable as Direct Immunofluorescence? A Systematic Review, Meta-Analysis, and Trial Sequential Analysis. [PDF]
Patini R +9 more
europepmc +1 more source
The skin as a sentinel organ for neurodegeneration: An underrecognized target for dementia prevention. [PDF]
Han Y, Zhou C, Wang P, Karako K, Song P.
europepmc +1 more source

